caa a22 4500 477055958 CHVBK 20180405111346.0 cr unu---uuuuu 170330e19961201xx s 000 0 eng 10.1007/s002280050190 doi (NATIONALLICENCE)springer-10.1007/s002280050190 Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1) [Elektronische Daten] [P. Scheffler, J. Gross, T. Markwirth, J. Maier, H. Schieffer] Objective: We compared the efficacy of a bolus injection (5 min) of LIPO-PGE1 (Prostaglandin E1 in lipid emulsion) with conventional PGE1-cyclodextrin (PGE1-cyclodextrin) infusions (2 h) in patients with intermittent claudication. The quantitative blood-flow in the common femoral artery was measured using a computerized ultrasound Doppler system (MAVIS®). we also monitored the transcutaneous oxygen pressure, the skin temperature on the foot, and the reactive change in blood pressure and pulse as well as side effects. Results : Dose finding of LIPO-PGE1: After bolus injection of 30, 50, and 80 μg LIPO-PGE1 a significant dose-dependent increase of the blood flow in the leg (+ 96.9%, 80 μg) with a peak 3 h after injection was seen. After LIPO-PGE1 we observed an enhanced microcirculation (significant rise in the transcutaneous oxygen pressure and the skin temperature on the foot). We noted longer lasting pharmacodynamic properties with LIPO-PGE1 (50 μg) compared to PGE1-cyclodextrin (60 μg). Comparison to PGE1-cyclodextrin: In a cross-over, placebo-controlled study, 20 patients with intermittent claudication received 4 weeks therapy with a bolus of 50 μg LIPO-PGE1 or a 2 h infusion of 60 μg PGE1-cyclodextrin per day. A significant increase in the blood flow was measured at the end of 4 weeks therapy compared to the initial values before treatment. This rise correlates significantly with the increase in the patient's maximal walking distance (+112%, LIPO-PGE1). Compared to conventional PGE1-cyclodextrin infusions given over 2 h, a clearly prolonged increase in perfusion of the affected limb after LIPO-PGE1 was demonstrated. No serious adverse effects were observed. Springer-Verlag Berlin Heidelberg, 1996 Key words LIPO-Prostaglandin E1 nationallicence intermittent claudication nationallicence haemodynamics nationallicence quantitative blood flow measurement nationallicence transcutaneous oxygen pressure nationallicence walking distance nationallicence Scheffler P. III Medizinische Klinik, Universitätskliniken des Saarlandes, D-66421 Homburg/Saar, Germany, DE aut Gross J. III Medical Clinic (Cardiology and Angiology), University Hospital, D-66421 Homburg/Saar, Germany, DE aut Markwirth T. III Medical Clinic (Cardiology and Angiology), University Hospital, D-66421 Homburg/Saar, Germany, DE aut Maier J. III Medical Clinic (Cardiology and Angiology), University Hospital, D-66421 Homburg/Saar, Germany, DE aut Schieffer H. III Medical Clinic (Cardiology and Angiology), University Hospital, D-66421 Homburg/Saar, Germany, DE aut https://doi.org/10.1007/s002280050190 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050190 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Scheffler P. III Medizinische Klinik, Universitätskliniken des Saarlandes, D-66421 Homburg/Saar, Germany, DE aut NATIONALLICENCE 700 1- Gross J. III Medical Clinic (Cardiology and Angiology), University Hospital, D-66421 Homburg/Saar, Germany, DE aut NATIONALLICENCE 700 1- Markwirth T. III Medical Clinic (Cardiology and Angiology), University Hospital, D-66421 Homburg/Saar, Germany, DE aut NATIONALLICENCE 700 1- Maier J. III Medical Clinic (Cardiology and Angiology), University Hospital, D-66421 Homburg/Saar, Germany, DE aut NATIONALLICENCE 700 1- Schieffer H. III Medical Clinic (Cardiology and Angiology), University Hospital, D-66421 Homburg/Saar, Germany, DE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer